In Canada, these include the use of TTR protein stabilizers, which are currently indicated to treat ATTR cardiomyopathy, and the use of TTR gene silencers, which are currently indicated to treat ATTRv polyneuropathy. Here, TTR is linked to cardiomyopathy.